Shape, not just size, impacts effectiveness of emerging nanomedicine therapies

August 4, 2008

In the budding field of nanotechnology, scientists already know that size does matter. But now, researchers at the University of North Carolina at Chapel Hill have shown that shape matters even more — a finding that could lead to new and more effective methods for treating cancer and other diseases, from diabetes and multiple sclerosis to arthritis and obesity.

A team of researchers led by Joseph DeSimone, Ph.D., Chancellor's Eminent Professor of Chemistry in UNC's College of Arts and Sciences and William R. Kenan, Jr. Distinguished Professor of Chemical Engineering at North Carolina State University, and Stephanie Gratton, a graduate student in DeSimone's lab, have demonstrated that nanoparticles designed with a specific shape, size and surface chemistry are taken up into cells and behave differently within cells depending on these attributes.

Their findings appear in this week's online early edition of the journal PNAS, the Proceedings of the National Academy of Sciences.

Using nanoparticles to combat cancer is an area of interest for many researchers. For decades, treating the disease has mostly involved injecting patients with toxic drugs – a practice in which only a fraction of the drugs reach the intended target, killing healthy cells in the process and causing harmful side effects.

Previous studies have shown that drug-carrying nanoparticles can hone-in on and attack tumors, in part because of their extremely small size — less than 100 nanometers (one nanometer = one billionth of a meter) — which helps allow them to pass through cell membranes. However, up until now, existing techniques have meant that targeting agents could only be delivered using spherical or granular shaped particles.

Using PRINT® (Particle Replication in Non-wetting Templates) technology — a technique invented in DeSimone's lab that allows scientists to design and produce "custom-made" nanoparticles — the UNC researchers made particles with specific shapes, sizes and surface charges. DeSimone said the aim is to optimize particle attributes for specific therapeutic objectives.

"This would mean that we could deliver lower dosages of drugs to specific cells and tissues in the body and actually be more effective in treating the cancer," said DeSimone, who is also a member of UNC's Lineberger Comprehensive Cancer Center and the co-principal investigator for the Carolina Center for Cancer Nanotechnology Excellence.

Creating particles of different dimensions, the UNC researchers changed one variable at a time, and experimented with different surface chemistries. They then incubated the different particles with human cervical carcinoma epithelial (HeLa) cells, monitoring each type to see which ones the cells absorbed most effectively.

For instance, the scientists discovered that long, rod-shaped particles (diameter, 150 nanometers; height, 450 nanometers) were internalized by cells approximately four times faster than lower aspect ratio particles (diameter, 200 nanometers; height, 200 nanometers), and traveled significantly further into the cells as well.

Gratton noted the same phenomenon is found in natural organisms.

"The long rod-shaped structure of bacteria may help explain why PRINT® particles of higher aspect ratios are internalized more rapidly and effectively than lower aspect ratio particles," she said. "If we can design particles that rely on the same mechanisms that nature has perfected for bacteria, we may unlock the key for delivering therapeutics more efficiently and effectively to treat and cure disease."

Liquidia Technologies, a UNC spin-off company, has an exclusive license to the PRINT® technology and is developing engineered nanoparticles for delivery of nucleic acids and small molecule therapeutics. Liquidia also sponsors research in the DeSimone lab. The company's chief executive officer, Neal Fowler, said the study's findings should prove of interest to the biopharmaceutical industry.

"We are delighted to contribute to the important work that Professor DeSimone and his students are undertaking in the field of nanomedicine. This work answers key questions about the role of particle shape and size that industry leaders have been asking for some time," Fowler said.

Source: University of North Carolina at Chapel Hill

Explore further: Researchers use DNA-based nano-tweezers to measure the forces between nucleosomes

Related Stories

Epstein-Barr virus and cancer: New tricks from an old dog

February 13, 2017

After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms. About one third of infected teenagers and young adults nevertheless ...

Refined method offers new piece in the cancer puzzle

February 8, 2017

A special spectrometry method that is normally used in analyses of computer chips, lacquers and metals has been further developed at the University of Gothenburg so that it can help researchers better detect harmful cells ...

Nanoparticle screen could speed up drug development

February 8, 2017

Many scientists are pursuing ways to treat disease by delivering DNA or RNA that can turn a gene on or off. However, a major obstacle to progress in this field has been finding ways to safely deliver that genetic material ...

Recommended for you

Chemical reaction alters the colours of plasmonic prints

March 1, 2017

Plasmonic printing produces resolutions several times greater than conventional printing methods. In plasmonic printing, colours are formed on the surfaces of tiny metallic particles when light excites their electrons to ...

Nano 'sandwich' offers unique properties

February 27, 2017

Rice University researchers have modeled a nanoscale sandwich, the first in what they hope will become a molecular deli for materials scientists.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.